Work

Impacts of Oliceridine versus Sufentanil on the Quality of Postoperative Recovery in Elective Gynecological Laparoscopic Surgery: A Randomized Controlled Trial

Year: 2026

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: Background: Oliceridine is a novel μ-opioid receptor agonist selectively activating the G protein signaling pathway. This study aimed to explore the influences of patient-controlled intravenous analgesia (PCIA) employing oliceridine and sufentanil on the postoperative recovery of patients undergoing elective laparoscopic gynecological surgery. Methods: This study included 136 patients aged 18– 65 years who were randomized to receive elective gynecological laparoscopic surgery under general anaesthesia with administering PCIA with oliceridine or sufentanil. The primary outcome was the Quality of Recovery - 15 (QoR-15) score on postoperative day 1 (POD 1). Secondary outcome measures comprised: the overall benefit of analgesic score (OBAS) on POD 1; time to first flatus; time to first ambulation; postoperative hospital stay; QoR-15 score on POD 2 and 3; PCIA total injected drugs; the number of patients requiring rescue analgesia and rescue antiemetics; VAS scores from T 1 to T 6 , and MOAA/S scores from T 1 to T 5 ; the incidence rate of adverse events; perioperative vital signs. Results: In the primary ITT analysis using multiple imputation (n=136), analysis of covariance adjusting for baseline QoR‑15 score showed that the group O had significantly higher QoR‑15 scores on POD 1 than the group S, with the adjusted mean difference of 11.94 points (95% CI: 10.02– 13.86; p < 0.001). Statistical differences between the two groups were observed in POD 1 OBAS score, time to first flatus, time to first ambulation, hospital discharge duration, and QoR-15 scores on POD 2 and 3. In addition, compared with the sufentanil group, the oliceridine group was observed to have a lower incidence of opioid-related adverse events. Conclusion: In this single-center study of relatively young and healthy female patients undergoing gynecologic laparoscopic surgery, oliceridine demonstrated superior recovery quality compared with sufentanil, with a between-group difference exceeding the 6-point MCID threshold. It also significantly accelerated gastrointestinal recovery, shortened hospital stay. Trial Registration: This study was registered with the Chinese Clinical Trial Registry (ChiCTR2400090783). Keywords: oliceridine, sufentanil, the quality of postoperative recovery, gynecological laparoscopic surgery

Source: Drug Design Development and Therapy

DOI: 10.2147/dddt.s612360